Consumer safety notice Home About Hikma Our businesses Quickfinder About Hikma Message from the chairman Hikma factsheet Our mission & vision Our values Our strengths Our history Our businesses Our management Our partners Corporate governance Keep yourself updated about Hikma Stay informed Learn more about Hikma worldwide Our partners View our partners or find business development contacts Our businesses Branded Our largest business is our Branded business which focuses on the MENA region. This develops, manufactures, and markets branded generics and a portfolio of in-licensed products, many of which are still patent protected. We understand that consumer trust is of utmost importance in our industry, and for this reason, we are focused on maintaining consistently high standards. For more than 30 years we have built a reputation for our quality. As a result, we have become the partner of choice in the MENA region. Focus on the MENA region Our branded business is focused on the MENA region, with sales across 18 MENA markets. In the MENA, we are the largest regional pharmaceutical company and among the five largest pharmaceutical company overall through the branded business Broad product portfolio Our branded business sells 499 solid, semi-solid and liquid products in 1,256 dosage strengths and forms. Our core strengths lie in the field of anti-infectives, and we are increasing our focus on the cardiovascular, CNS, and diabetes therapeutic areas. Powerful marketing capability Our sales and marketing team, which is composed of around 2000 employees, is one of the largest in the MENA Region. Their efforts have enabled us to build close relationships with key stakeholders and to optimise the commercial potential of the products we market. Local manufacturing Our branded pharmaceuticals are manufactured at our facilities in Jordan, Algeria, Saudi Arabia, Egypt, Tunisia and Morocco. Facilities in Jordan and Saudi Arabia have been successfully inspected by the US FDA and MHRA. Proven track record with In-licensors Our strong presence in the MENA region makes us an attractive partner for multinational pharmaceutical companies seeking access to the region. Our partnerships enrich our portfolio with innovative and high quality affordable medications, including recently the introduction of biosimilar products. Generics Our Generics business is entirely focused on the US market for oral generics. We focus on quality manufacturing and high service levels, with a strong emphasis on niche products, including controlled substances. The business leverages our efficient and lower cost manufacturing facilities MENA. Broad product range The Generics business operates as West-Ward Pharmaceuticals, a domestic marketer and manufacturer of generic pharmaceutical products, selling 11 products in 44 dosage forms and strengths. West-Ward markets a broad range of therapeutic areas including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory, hormonal and others. Dosage forms marketed by West-Ward include tablets, capsules, solutions and suspensions. Strong market position Our Generics products are marketed to chain stores, wholesalers, distributors, health systems and governmental agencies. Our experienced sales representatives and customer service teams are organised to meet the needs of our customers with the support of our world-class manufacturing facilities and an exemplary regulatory record. Focus on service As a long-standing generic prescription provider in the US, we strive to provide the highest levels of customer service in the US whilst improving the lives of patients everyday. Injectables With a growing presence in the MENA Region, Europe and the United States, we are becoming a leading manufacturer of generic injectables. Our US FDA approved manufacturing facilities offer a range of manufacturing capabilities including sterile liquid, powder, lyophilised and cytotoxic products. Within this niche market, we offer a broad product portfolio including CNS, anti-infectives, cardiovascular and oncology products. Leading global injectables manufacturer We are rapidly growing our global injectables business, particularly in the US, where we have a strong market position. Our strategic focus on higher value, differentiated products and continued investments in technologies and operational excellence. Ability to produce all three injectables forms We produce powder, liquid and lyophilised injectables at our US FDA approved facilities in US, Portugal and Germany. Our facility in the US has a wide range of therapeutic categories including controlled substances. Our manufacturing operations are supported by our extensive R&D capabilities in injectables. Our broad range of products Our generic branded and non-branded injectable products span a broad range of therapeutic categories, including CNS, anti-infectives, cardiovascular and oncological therapeutic areas. Our injectables business markets 200 branded and non-branded injectable products in 379 dosage strengths and forms, including several in-licensed products. Contact us Stay informed Site map Terms and conditions Disclaimer Privacy policy Cookies policy © Hikma Pharmaceuticals PLC 2015